Loading
Luminex Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Eck Stephen L., was filed 30 Nov 2020.
Luminex Corp: what insiders have been doing
Luminex Corp, founded in 1995, is a Healthcare & Pharma company based in Austin, United States. Its latest reported headcount is 1,080 employees (2023). Its directors and officers file their transactions with SEC (Form 4). No insider at Luminex Corp has published a filing in the past twelve months. The most recent one dates from 15 July 2021.
Our records for Luminex Corp go back to 2016, with 11 purchases and 82 sales on the open market in total.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
339
Thresholds
n/a
Buy Volume
€2M
11 ops. · all time
Sell Volume
€58M
82 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2020FY ended December 2020 · cache
Income statement
Revenue371.6M
Gross profit220.7M59% margin
Net income13.5M3.6% margin
Last declaration on 15 July 2021
Declarations339 total
33,586 shares@ US$37.0082.4% of flowCommon StockSEC:0001033905-21-000058:1
108,162 shares@ US$37.0057.7% of flowCommon StockSEC:0001033905-21-000059:1
60,694 shares@ US$37.0026.4% of flowCommon StockSEC:0001033905-21-000060:1
75,925 shares@ US$37.0070.4% of flowCommon StockSEC:0001033905-21-000062:1
50,133 shares@ US$37.0082.3% of flowCommon StockSEC:0001033905-21-000063:1
16,817 shares@ US$37.0084.9% of flowCommon StockSEC:0001033905-21-000064:1
30,266 shares@ US$37.0011.7% of flowCommon StockSEC:0001033905-21-000050:1
26,550 shares@ US$37.0013.9% of flowCommon StockSEC:0001033905-21-000051:1
34,784 shares@ US$37.0010.8% of flowCommon StockSEC:0001033905-21-000052:1
22,781 shares@ US$37.007.0% of flowCommon StockSEC:0001033905-21-000053:1
30,266 shares@ US$37.0010.2% of flowCommon StockSEC:0001033905-21-000054:1
27,478 shares@ US$37.0021.0% of flowCommon StockSEC:0001033905-21-000055:1
88,798 shares@ US$37.007.8% of flowCommon StockSEC:0001033905-21-000056:1
22,001 shares@ US$37.0022.8% of flowCommon StockSEC:0001033905-21-000057:1
79,204 shares@ US$37.00100.0% of flowCommon StockSEC:0001033905-21-000059:0
24,443 shares@ US$37.00100.0% of flowCommon StockSEC:0001033905-21-000062:0
3,000 shares@ US$37.00100.0% of flowCommon StockSEC:0001033905-21-000064:0
152,372 shares@ US$37.00100.0% of flowCommon StockSEC:0001033905-21-000056:0
20,098 shares@ US$37.00100.0% of flowCommon StockSEC:0001033905-21-000055:0
24,524 shares@ US$37.00100.0% of flowCommon StockSEC:0001033905-21-000053:0
23,244 shares@ US$37.00100.0% of flowCommon StockSEC:0001033905-21-000051:0
6,955 shares@ US$37.00100.0% of flowCommon StockSEC:0001033905-21-000061:0
24,963 shares@ US$37.00100.0% of flowCommon StockSEC:0001033905-21-000057:0
19,710 shares@ US$37.00100.0% of flowCommon StockSEC:0001033905-21-000054:0
208,909 shares@ US$37.00100.0% of flowCommon StockSEC:0001033905-21-000052:0
25 of 339 declarations
About Luminex Corp
Luminex Corp. (ticker LMNX) was a United States-based diagnostics and life-sciences company that traded on the NASDAQ before being acquired by DiaSorin in a transaction completed in 2021. For investors, Luminex is best understood as a specialty molecular diagnostics platform company headquartered in Austin, Texas, with a long track record in proprietary biological testing technologies. The company was founded in the late 1990s and built its franchise around multiplex testing, a format that allows multiple biomarkers or pathogens to be detected from a single sample, an important differentiator in clinical diagnostics and research workflows.
Luminex’s business model combined instruments, consumables, and proprietary assays. That mix was strategically attractive because installed instruments tended to generate recurring demand for related reagents and tests, creating a relatively sticky customer relationship. The company served clinical laboratories, hospitals, research institutions, and selected pharmaceutical and applied-life-science customers. Its core product areas included molecular microbiology, immunodiagnostics, genetic typing, and syndromic testing applications. In practice, Luminex positioned itself as a technology supplier for higher-value niche segments of the diagnostics market rather than as a broad-based commodity test provider.
Read moreShow less
From a competitive standpoint, Luminex was recognized for its strength in multiplex molecular diagnostics, where performance, workflow efficiency, assay breadth, and integration with laboratory systems matter as much as price. The company competed against larger diversified diagnostics groups as well as specialized innovators. Its moat was therefore based on platform know-how, a differentiated menu of tests, and the ability to grow around an existing instrument base. That said, the business also faced the usual pressures of the diagnostics industry, including reimbursement dynamics, regulatory requirements, and the need for continuous product innovation.
Geographically, Luminex was primarily anchored in the United States, while also reaching customers internationally through direct and indirect commercial channels. Key milestones over the years included the acquisition of Nanosphere in 2016 and other portfolio-expanding moves aimed at strengthening the company’s molecular microbiology and diagnostic capabilities. The most important recent corporate event was the acquisition by DiaSorin, which ended Luminex’s standalone life as a public company on the NASDAQ. For investors analyzing LMNX historically, the company illustrates how a specialist diagnostics platform can build value through proprietary technology, recurring consumables, and sector consolidation.
